13 results on '"ZHU Jiye"'
Search Results
2. Guidelines for the Diagnosis and Treatment of Primary Liver Cancer (2022 Edition)
- Author
-
Zhou, Jian, Sun, Huichuan, Wang, Zheng, Cong, Wenming, Zeng, Mengsu, Zhou, Weiping, Bie, Ping, Liu, Lianxin, Wen, Tianfu, Kuang, Ming, Han, Guohong, Yan, ZhiPing, Wang, Maoqiang, Liu, Ruibao, Lu, Ligong, Ren, Zhenggang, Zeng, ZhaoChong, Liang, Ping, Liang, Changhong, Chen, Min, Yan, Fuhua, Wang, Wenping, Hou, Jinlin, Ji, Yuan, Yun, Jingping, Bai, Xueli, Cai, Dingfang, Chen, Weixia, Chen, Yongjun, Cheng, Wenwu, Cheng, Shuqun, Dai, Chaoliu, Guo, Wenzhi, Guo, Yabing, Hua, Baojin, Huang, Xiaowu, Jia, Weidong, Li, Qiu, Li, Tao, Li, Xun, Li, Yaming, Li, Yexiong, Liang, Jun, Ling, Changquan, Liu, Tianshu, Liu, Xiufeng, Lu, Shichun, Lv, Guoyue, Mao, Yilei, Meng, Zhiqiang, Peng, Tao, Ren, Weixin, Shi, Hongcheng, Shi, Guoming, Shi, Ming, Song, Tianqiang, Tao, Kaishan, Wang, Jianhua, Wang, Kui, Wang, Lu, Wang, Wentao, Wang, Xiaoying, Wang, Zhiming, Xiang, Bangde, Xing, Baocai, Xu, Jianming, Yang, Jiamei, Yang, Jianyong, Yang, Yefa, Yang, Yunke, Ye, Shenglong, Yin, Zhenyu, Zeng, Yong, Zhang, Bixiang, Zhang, Boheng, Zhang, Leida, Zhang, Shuijun, Zhang, Ti, Zhang, Yanqiao, Zhao, Ming, Zhao, Yongfu, Zheng, Honggang, Zhou, Ledu, Zhu, Jiye, Zhu, Kangshun, Liu, Rong, Shi, Yinghong, Xiao, Yongsheng, Zhang, Lan, Yang, Chun, Wu, Zhifeng, Dai, Zhi, Chen, Minshan, Cai, Jianqiang, Wang, Weilin, Cai, Xiujun, Li, Qiang, Shen, Feng, Qin, Shukui, Teng, Gaojun, Dong, Jiahong, and Fan, Jia
- Abstract
Background:Primary liver cancer, of which around 75–85% is hepatocellular carcinoma in China, is the fourth most common malignancy and the second leading cause of tumor-related death, thereby posing a significant threat to the life and health of the Chinese people. Summary:Since the publication of Guidelines for Diagnosis and Treatment of Primary Liver Cancer in China in June 2017, which were updated by the National Health Commission in December 2019, additional high-quality evidence has emerged from researchers worldwide regarding the diagnosis, staging, and treatment of liver cancer, that requires the guidelines to be updated again. The new edition (2022 Edition) was written by more than 100 experts in the field of liver cancer in China, which not only reflects the real-world situation in China but also may reshape the nationwide diagnosis and treatment of liver cancer. Key Messages:The new guideline aims to encourage the implementation of evidence-based practice and improve the national average 5-year survival rate for patients with liver cancer, as proposed in the “Health China 2030 Blueprint.”
- Published
- 2023
- Full Text
- View/download PDF
3. Isoformic PD-1-mediated immunosuppression underlies resistance to PD-1 blockade in hepatocellular carcinoma patients
- Author
-
Tan, Zhiwu, Chiu, Mei Sum, Yang, Xinxiang, Yue, Ming, Cheung, Tan To, Zhou, Dongyan, Wang, Yuewen, Chan, Anthony Wing-Hung, Yan, Chi Wing, Kwan, Ka Yi, Wong, Yik Chun, Li, Xin, Zhou, Jingying, To, Ka Fai, Zhu, Jiye, Lo, Chung Mau, Cheng, Alfred Sze-Lok, Chan, Stephen Lam, Liu, Li, Song, You-Qiang, Man, Kwan, and Chen, Zhiwei
- Abstract
ObjectiveImmune checkpoint blockade (ICB) has improved cancer treatment, yet why most hepatocellular carcinoma (HCC) patients are resistant to PD-1 ICB remains elusive. Here, we elucidated the role of a programmed cell death protein 1 (PD-1) isoform, Δ42PD-1, in HCC progression and resistance to nivolumab ICB.DesignWe investigated 74 HCC patients in three cohorts, including 41 untreated, 28 treated with nivolumab and 5 treated with pembrolizumab. Peripheral blood mononuclear cells from blood samples and tumour infiltrating lymphocytes from tumour tissues were isolated for immunophenotyping. The functional significance of Δ42PD-1 was explored by single-cell RNA sequencing analysis and validated by functional and mechanistic studies. The immunotherapeutic efficacy of Δ42PD-1 monoclonal antibody was determined in HCC humanised mouse models.ResultsWe found distinct T cell subsets, which did not express PD-1 but expressed its isoform Δ42PD-1, accounting for up to 71% of cytotoxic T lymphocytes in untreated HCC patients. Δ42PD-1+T cells were tumour-infiltrating and correlated positively with HCC severity. Moreover, they were more exhausted than PD-1+T cells by single T cell and functional analysis. HCC patients treated with anti-PD-1 ICB showed effective PD-1 blockade but increased frequencies of Δ42PD-1+T cells over time especially in patients with progressive disease. Tumour-infiltrated Δ42PD-1+T cells likely sustained HCC through toll-like receptors-4-signalling for tumourigenesis. Anti-Δ42PD-1 antibody, but not nivolumab, inhibited tumour growth in three murine HCC models.ConclusionOur findings not only revealed a mechanism underlying resistance to PD-1 ICB but also identified anti-Δ42PD-1 antibody for HCC immunotherapy.
- Published
- 2023
- Full Text
- View/download PDF
4. Liver tumour immune microenvironment subtypes and neutrophil heterogeneity
- Author
-
Xue, Ruidong, Zhang, Qiming, Cao, Qi, Kong, Ruirui, Xiang, Xiao, Liu, Hengkang, Feng, Mei, Wang, Fangyanni, Cheng, Jinghui, Li, Zhao, Zhan, Qimin, Deng, Mi, Zhu, Jiye, Zhang, Zemin, and Zhang, Ning
- Abstract
The heterogeneity of the tumour immune microenvironment (TIME), organized by various immune and stromal cells, is a major contributing factor of tumour metastasis, relapse and drug resistance1–3, but how different TIME subtypes are connected to the clinical relevance in liver cancer remains unclear. Here we performed single-cell RNA-sequencing (scRNA-seq) analysis of 189 samples collected from 124 patients and 8 mice with liver cancer. With more than 1 million cells analysed, we stratified patients into five TIME subtypes, including immune activation, immune suppression mediated by myeloid or stromal cells, immune exclusion and immune residence phenotypes. Different TIME subtypes were spatially organized and associated with chemokine networks and genomic features. Notably, tumour-associated neutrophil (TAN) populations enriched in the myeloid-cell-enriched subtype were associated with an unfavourable prognosis. Through in vitro induction of TANs and ex vivo analyses of patient TANs, we showed that CCL4+TANs can recruit macrophages and that PD-L1+TANs can suppress T cell cytotoxicity. Furthermore, scRNA-seq analysis of mouse neutrophil subsets revealed that they are largely conserved with those of humans. In vivo neutrophil depletion in mouse models attenuated tumour progression, confirming the pro-tumour phenotypes of TANs. With this detailed cellular heterogeneity landscape of liver cancer, our study illustrates diverse TIME subtypes, highlights immunosuppressive functions of TANs and sheds light on potential immunotherapies targeting TANs.
- Published
- 2022
- Full Text
- View/download PDF
5. Guidelines for the Diagnosis and Treatment of Hepatocellular Carcinoma (2019 Edition)
- Author
-
Zhou, Jian, Sun, Huichuan, Wang, Zheng, Cong, Wenming, Wang, Jianhua, Zeng, Mengsu, Zhou, Weiping, Bie, Ping, Liu, Lianxin, Wen, Tianfu, Han, Guohong, Wang, Maoqiang, Liu, Ruibao, Lu, Ligong, Ren, Zhengang, Chen, Minshan, Zeng, Zhaochong, Liang, Ping, Liang, Changhong, Chen, Min, Yan, Fuhua, Wang, Wenping, Ji, Yuan, Yun, Jingping, Cai, Dingfang, Chen, Yongjun, Cheng, Wenwu, Cheng, Shuqun, Dai, Chaoliu, Guo, Wenzhi, Hua, Baojin, Huang, Xiaowu, Jia, Weidong, Li, Yaming, Li, Yexiong, Liang, Jun, Liu, Tianshu, Lv, Guoyue, Mao, Yilei, Peng, Tao, Ren, Weixin, Shi, Hongcheng, Shi, Guoming, Tao, Kaishan, Wang, Wentao, Wang, Xiaoying, Wang, Zhiming, Xiang, Bangde, Xing, Baocai, Xu, Jianming, Yang, Jiamei, Yang, Jianyong, Yang, Yefa, Yang, Yunke, Ye, Shenglong, Yin, Zhengyu, Zhang, Bixiang, Zhang, Boheng, Zhang, Leida, Zhang, Shuijun, Zhang, Ti, Zhao, Yongfu, Zheng, Honggang, Zhu, Jiye, Zhu, Kangshun, Liu, Rong, Shi, Yinghong, Xiao, Yongsheng, Dai, Zhi, Teng, Gaojun, Cai, Jianqiang, Wang, Weilin, Cai, Xiujun, Li, Qiang, Shen, Feng, Qin, Shukui, Dong, Jiahong, and Fan, Jia
- Abstract
Background:Primary liver cancer, around 90% are hepatocellular carcinoma in China, is the fourth most common malignancy and the second leading cause of tumor-related death, thereby posing a significant threat to the life and health of the Chinese people. Summary:Since the publication of Guidelines for Diagnosis and Treatment of Primary Liver Cancer (2017 Edition)in 2018, additional high-quality evidence has emerged with relevance to the diagnosis, staging, and treatment of liver cancer in and outside China that requires the guidelines to be updated. The new edition (2019 Edition)was written by more than 70 experts in the field of liver cancer in China. They reflect the real-world situation in China regarding diagnosing and treating liver cancer in recent years. Key Messages:Most importantly, the new guidelines were endorsed and promulgated by the Bureau of Medical Administration of the National Health Commission of the People’s Republic of China in December 2019.
- Published
- 2020
- Full Text
- View/download PDF
6. TIGIT Can Exert Immunosuppressive Effects on CD8+T Cells by the CD155/TIGIT Signaling Pathway for Hepatocellular Carcinoma In Vitro
- Author
-
Zhang, Changkun, Wang, Yang, Xun, Xiaodong, Wang, Siqi, Xiang, Xiao, Hu, Shihua, Cheng, Qian, Guo, Jinghang, Li, Zhao, and Zhu, Jiye
- Abstract
Supplemental Digital Content is available in the text.The efficacy of adoptive cellular immunotherapy against cancer cells is limited due to the presence of immunosuppressive cells within the solid tumor microenvironment. The upregulation of certain coinhibitory receptors may lead to exhaustion of the immune effector cells. T-cell immunoglobulin and immunoreceptor tyrosine-based inhibitory motif domain (TIGIT) is an immune inhibitory receptor expressed by regulatory T cells and activated T cells and natural killer cells. The aim of this study was to determine the immunosuppressive effects of CD155/TIGIT signaling on CD8+T cells of adoptive cellular immunotherapy in hepatocellular carcinoma (HCC). Our studies found that CD155 was overexpressed in HCC, and CD155hiHCC cells upregulated TIGIT on CD8+T cells, which decreased the secretion of interferon-γ, tumor necrosis factor-α, and interleukin-17A and increased that of interleukin-10 from the effector cells. However, TIGIT blockade or CD155-knockdown reversed the inhibitory effect of HCC cells on CD8+T-cell effector function. These results indicate that TIGIT can exert an immunosuppressive effect on CD8 T cells by modulating cytokine production through CD155, and is a promising target to optimize adoptive cellular immunotherapy against HCC.
- Published
- 2020
- Full Text
- View/download PDF
7. Hematopoietic-substrate-1 associated protein X-1 (HAX-1) regulates liver cancer cells growth, metastasis, and angiogenesis through Akt
- Author
-
Wu, Zhenyu, Ai, Xiangnan, Hu, Hao, Wang, Siqi, Wang, Yang, Kang, Feng, Ouyang, Caiguo, and Zhu, Jiye
- Abstract
ABSTRACTThe aim of this study was to investigate the effects and mechanisms of hematopoietic-substrate-1-associated protein X-1 (HAX-1) on liver cancer cells. Information on HAX-1 from liver cancer patients was analyzed by the Cancer Genome Atlas (TCGA) program. Cell migration and invasion abilities were respectively tested by scratch assay and transwell assay. Tube formation assay was applied to detect angiogenesis protein and mRNA was determined using quantitative real-time polymerase chain reaction (qRT-PCR) and Western blot. We found that the median month survival of HAX-1 overexpressing liver cancer patients was shorter than that of HAX-1 normal liver cancer patients. HAX-1 was overexpressed in liver cancer tissues and cells, and HAX-1 overexpression promoted the liver cancer cells growth, migration, and invasion, whereas silencing HAX-1 produced the opposite results. Inhibition of Akt by LY294002 reversed the migration and invasion abilities of liver cancer cells, and inhibited the ability of cells growth and angiogenesis. Silencing PIK3CA enhanced the inhibitory effects of HAX-1 silencing on the viability, migration, and invasion of liver cancer cells. HAX-1 affected liver cancer cells metastasis and angiogenesis by affecting Akt phosphorylation and FOXO3A expression.
- Published
- 2019
- Full Text
- View/download PDF
8. Clinical efficacy and safety of regorafenib for patients with recurrent hepatocellular carcinoma after hepatectomy: A real-world study in China.
- Author
-
Ni, Yanbin, Zheng, Jiaxi, Wang, Yang, Li, Zhao, Zhu, JiYe, and Gao, Jie
- Published
- 2023
- Full Text
- View/download PDF
9. Iodine-125 implantation plus transarterial chemoembolization for the treatment of hepatocellular carcinoma of 3–5 cm: A propensity score matching study.
- Author
-
Li, Minpeng, He, Jun, Pan, Meng, Yu, Yuan, Pan, Zhuang, Xu, Bin, and Zhu, Jiye
- Abstract
Background Both iodine-125 implantation and transarterial chemoembolization (TACE) are feasible options for hepatocellular carcinoma (HCC). The aim of the research is to investigate whether iodine-125 implantation combined with TACE could improve the overall survival of patients with HCC of 3–5 cm. Methods 144 patients with HCC of 3–5 cm who underwent iodine-125 implantation plus TACE and TACE alone were retrospectively enrolled in this study. To reduce the selection bias, 55 matched pairs of patients were generated by propensity score matching (PSM). Their overall survival was compared by the Kaplan–Meier method. Independent prognostic factors were identified by Cox proportional hazards regression model. Results patients receiving iodine-125 implantation plus TACE have significantly better overall survival than patients receiving TACE alone ( P < 0.001). After PSM, treatment of iodine-125 plus TACE still provide better survival (1-year, 89.1% vs. 65.5%; 3-year, 51.0% vs. 7.4%; P < 0.001). In multivariate analysis, BCLC stage, vascular invasion and treatment modality independently predicted the prognosis. No severe adverse events occurred in both groups. Conclusion for HCC patients of 3–5 cm for whom surgical intervention is not an option, iodine-125 implantation combined with TACE might be an effective and viable alternative to provide better overall survival. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
10. Microenvironment of a tumor-organoid system enhances hepatocellular carcinoma malignancy-related hallmarks
- Author
-
Wang, Yang, Takeishi, Kazuki, Li, Zhao, Cervantes-Alvarez, Eduardo, Collin de l'Hortet, Alexandra, Guzman-Lepe, Jorge, Cui, Xiao, and Zhu, Jiye
- Abstract
ABSTRACTOrgan-like microenviroment and 3-dimensional (3D) cell culture conformations have been suggested as promising approaches to mimic in a micro-scale a whole organ cellular functions and interactions present in vivo. We have used this approach to examine biologic features of hepatocellular carcinoma (HCC) cells. In this study, we demonstrate that hepatocellular carcinoma (HCC) cells, fibroblasts, endothelial cells and extracellular matrix can generate organoid-like spheroids that enhanced numerous features of human HCC observed in vivo. We show that the addition of non-parenchymal cells such as fibroblast and endothelial cells is required for spheroid formation as well as the maintenance of the tissue-like structure. Furthermore, HCC cells cultured as spheroids with non-parenchymal cells express more neo-angiogenesis-related markers (VEGFR2, VEGF, HIF-α), tumor-related inflammatory factors (CXCR4, CXCL12, TNF-α) and molecules-related to induced epithelial-mesenchymal transition (TGFβ, Vimentin, MMP9) compared with organoids containing only HCC cells.These results demonstrate the importance of non-parenchymal cells in the cellular composition of HCC organoids. The novelty of the multicellular-based organotypic culture system strongly supports the integration of this approach in a high throughput approach to identified patient-specific HCC malignancy and accurate anti-tumor therapy screening after surgery.
- Published
- 2017
- Full Text
- View/download PDF
11. Current strategies to generate mature human induced pluripotent stem cells derived cholangiocytes and future applications
- Author
-
Cervantes-Alvarez, Eduardo, Wang, Yang, Collin de l'Hortet, Alexandra, Guzman-Lepe, Jorge, Zhu, Jiye, and Takeishi, Kazuki
- Abstract
ABSTRACTStem cell research has significantly evolved over the last few years, allowing the differentiation of pluripotent cells into almost any kind of lineage possible. Studies that focus on the liver have considerably taken a leap into this novel technology, and hepatocyte-like cells are being generated that are close to resembling actual hepatocytes both genotypically and phenotypically. The potential of this extends from disease models to bioengineering, and even also innovative therapies for end-stage liver disease. Nonetheless, too few attention has been given to the non-parenchymal cells which are also fundamental for normal liver function. This includes cholangiocytes, the cells of the biliary epithelium, without whose role in bile modification and metabolism would impair hepatocyte survival. Such can be observed in diseases that target them, so called cholangiopathies, for which there is much yet to study so as to improve therapeutical options. Protocols that describe the induction of human induced pluripotent stem cells into cholangiocytes are scarce, although progress is being achieved in this area as well. In order to give the current view on this emerging research field, and in hopes to motivate further advances, we present here a review on the known differentiation strategies with sight into future applications.
- Published
- 2017
- Full Text
- View/download PDF
12. Multi-Modal Imaging Probe for Glypican-3 Overexpressed in Orthotopic Hepatocellular Carcinoma
- Author
-
Feng, Shuo, Meng, Xiaoqing, Li, Zhao, Chang, Tse-Shao, Wu, Xiaoli, Zhou, Juan, Joshi, Bishnu, Choi, Eun-Young, Zhao, Lili, Zhu, Jiye, and Wang, Thomas D.
- Abstract
Hepatocellular carcinoma (HCC) is rising steadily in incidence, and more effective methods are needed for early detection and image-guided surgery. Glypican-3 (GPC3) is a cell surface biomarker that is overexpressed in early-stage cancer but not in cirrhosis. An IRDye800-labeled 12-mer amino acid sequence was identified, and specific binding to GPC3 was validated in vitroand in orthotopically implanted HCC tumors in vivo. Over 4-fold greater binding affinity and 2-fold faster kinetics were measured by comparison with previous GPC3 peptides. Photoacoustic images showed peak tumor uptake at 1.5 h post-injection and clearance within ∼24 h. Laparoscopic and whole-body fluorescence images showed strong intensity from tumor versus adjacent liver with about a 2-fold increase. Immunofluorescence staining of human liver specimens demonstrated specific binding to HCC versus cirrhosis with 79% sensitivity and 79% specificity, and normal liver with 81% sensitivity and 84% specificity. The near-infrared peptide is promising for early HCC detection in clinical trials.
- Published
- 2021
- Full Text
- View/download PDF
13. Clinicopathological features and differential diagnosis of hepatocellular carcinoma in extrahepatic metastases
- Author
-
Chen, Dingbao, Li, Zhao, Song, Qiujing, Qian, Lihua, Xie, Batubaiyin, Zhu, Jiye, and Bombardiere., Sergio Gonzalez
- Published
- 2018
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.